PDCD1 and obesity disorder: Obesity, therefore, plays a dual role; on the one hand, it promotes the development and progression of cancer through metabolic and immunological disorders, and on the other hand, it may increase the effectiveness of immunotherapies based on PD-1/PD-L1 checkpoint inhibitors [51].